Anaerobutyricum soehngenii improves glycemic control and other markers of cardio-metabolic health in adults at risk of type 2 diabetes
Authors:
- Ilias AttayeIAIlias Attaye
- Julia K. BirdJulia K. Bird
- Max NieuwdorpMNMax Nieuwdorp
- Sahin GülSGSahin Gül
- Jos F. M. L. SeegersJSJos F. M. L. Seegers
- Steven MorrisonSMSteven Morrison
- Stijn HofkensSHStijn Hofkens
- Hilde HerremaHHHilde Herrema
- Nam BuiNBNam Bui
- Marie-Luise PuhlmannMPMarie-Luise Puhlmann
- Willem M. de VosWVWillem M. de Vos
Open Access
- 15 May 2025
- journal article
- research article
- Published by Taylor & Francis in Gut Microbes
- Vol. 17 (1) , 2504115
Abstract
Anaerobutyricum soehngenii (previously Eubacterium hallii) is a butyrate-producing next-generation beneficial microbe generally recognized as safe. Several short-term intervention trials by A. soehngenii L2-7 have shown improvement of insulin sensitivity in prediabetic subjects and type 2 diabetes patients. To determine the long-term cardiometabolic benefits and safety, we performed a 3-month double-blind, randomized placebo-controlled intervention in 98 prediabetic insulin-resistant adults in Europe and U.S. with daily administration of encapsulated cells of A. soehngenii CH-106, a tetracycline-sensitive isogenic derivative of strain L2-7. Compared to placebo, A. soehngenii-treated subjects showed significantly reduced glycemic variability (1% reduction in the coefficient of variation; p = 0.01) and improved glycemic control (6% reduction in the overall net glycemic action-1; p < 0.05), including reduced serum glycated hemoglobin (HbA1c) levels when including the 4-week washout period (1 mmol/mol reduction; p < 0.05). Moreover, diastolic blood pressure was significantly reduced in all A. soehngenii-treated subjects (3 mm Hg; p < 0.05). The study product was well-tolerated and had no effect on the global intestinal microbiota composition, including alpha and beta-diversity, besides an increased abundance of A. soehngenii in the treatment group, indicative of compliance. The U.S. participants, compared to those in Europe, responded best, notably in the oral glucose tolerance tests (15% improvement in the area-under-the curve of plasma glucose levels; p = 0.039) or coefficient of variation (reduction of 3.1%; p < 0.05). This potentially relates to a more severe prediabetic state in U.S. subjects, associated with significantly reduced (1.5-3.5-fold) relative abundance of Bifidobacterium, Coprococcus, Ruminococcus spp. and two-fold increased relative abundance of Lachnoclostridium spp. In conclusion, daily oral supplementation with A. soehngenii was safe and improved various markers of glycemic control, reduced HbA1c levels and diastolic blood pressure, indicating a novel microbiome-based approach to improve cardio-metabolic health in adults at risk for developing type 2 diabetes.Clinical trial reg. no. NCT04529473, clinicaltrials.govSocial media summary 120 characters: Anaerobutyricum soehngenii supplementation improves #cardio-metabolic health in subjects at risk for type 2 #diabetes.Keywords
Funding Information
- ZonMW VICI (09150182010020)
- ERC-Advanced grant 2023 (101141346)
This publication has 51 references indexed in Scilit:
- phyloseq: An R Package for Reproducible Interactive Analysis and Graphics of Microbiome Census DataPLOS ONE, 2013
- Transfer of Intestinal Microbiota From Lean Donors Increases Insulin Sensitivity in Individuals With Metabolic SyndromeGastroenterology, 2012
- Genetic Basis of Tetracycline Resistance in Bifidobacterium animalis subsp. lactisApplied and Environmental Microbiology, 2010
- Comparative analysis of fecal DNA extraction methods with phylogenetic microarray: Effective recovery of bacterial and archaeal DNA using mechanical cell lysisJournal of Microbiological Methods, 2010
- Two Routes of Metabolic Cross-Feeding betweenBifidobacterium adolescentisand Butyrate-Producing Anaerobes from the Human GutApplied and Environmental Microbiology, 2006
- Glycaemic index methodologyNutrition Research Reviews, 2005
- Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trialsBMJ, 2003
- Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp.Diabetes Care, 1999
- Insulin resistance in obesity is associated with elevated basal lactate levels and diminished lactate appearance following intravenous glucose and insulinMetabolism, 1992
- The use of the glycemie Index in predicting the blood glucose response to mixed mealsThe American Journal of Clinical Nutrition, 1986